BNT324/DB-1311 Receives Fast Track Designation From FDA for mCRPC

[God_Loves_Me]

Fast track designation has been granted by the FDA to the antibody-drug conjugate (ADC) BNT324/DB-1311 to potentially treat patients with unresectable advanced or metastatic castration-resistant prostate cancer (mCRPC) whose disease had progressed on or after standard systemic regimens.1

The next-generation ADC is designed to target the transmembrane glycoprotein B7-H3, which is an immune checkpoint protein overexpressed in a variety of solid tumors and is associated with disease progression and poor prognosis. An ongoing phase 1/2 trial (NCT05914116) is evaluating BNT324/DB-1311 in patients with advanced solid tumors.

Source : oncnursingnews.com/view/bnt...